Clinical trials
11 active studies led by IDEAYA Biosciences, of 11 in all
Source: ClinicalTrials.gov, Studies with IDEAYA Biosciences (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 1Markets in public records
- 0Regions & countries
- 11Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by IDEAYA Biosciences or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on IDEAYA Biosciences
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Company facts
- Stock listing
- NASDAQ: IDYA
- Type
- Medicines
Source: SEC EDGAR, Company filings, CIK 1676725. Retrieved 13 Nov 2026.
See them on ClinicalTrials.gov (opens in a new tab)
SEC filings
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1676725.
Trials over time
Studies IDEAYA Biosciences leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with IDEAYA Biosciences or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show IDEAYA Biosciences: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets IDEAYA Biosciences is in.
From our blog
Stories on the topics IDEAYA Biosciences works in.
Collagen Supplements: Skin, Joints and Real Evidence
Collagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Read
Dermatology Diagnostics: AI and Skin Health
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read
Molecular Point-of-Care Tests: Lab Accuracy, Clinic Speed
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
Read